Released May 15, 2025, after the close
10-Q filed May 15, 2025, 45 days after period end · 0001683168-25-003705
Q1 2025 · 10-Q
Revenue—
Net Income-$6.32M-$6.32M N/M vs Q1 2024N/M vs Q4 2024
EPS Diluted-$0.32-$0.32 N/M vs Q1 2024no prior Q4 2024 on file
Operating Income-$6,365,584N/M
Operating Cash Flow-$4,618,740N/M
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|
| Net Income | -$6.32M | -$8.30M | -$5.27M |
| EPS Diluted | -$0.32 | -$5.40 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Actuate Therapeutics, Inc. · CIK 1652935 · Engraved from SEC EDGAR